Four Parkway North
About LundbeckLundbeck Inc. - Making a Difference One Patient at a Time
179 articles with Lundbeck
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Lundbeck selects Discngine’s 3decision® platform to leverage complex protein-ligand 3D structure data in the discovery of new treatments for brain diseases
Discngine announces that Lundbeck has selected its proprietary 3decision® collaborative platform to manage the pharma company’s structural knowledge related to protein and ligand 3D structures.
Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.
Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.
The government charged the three companies with using charitable foundations they financially supported to finance copays of Medicare and Medicaid patients, which is a violation of law.
Numerate and Lundbeck Partner to Apply AI Drug Discovery to Unlock Challenges of Neuroscience Research
Collaboration sets out to identify potential treatment candidates for disorders of the central nervous system including depression, psychosis, seizure and neurodegenerative disorders.
Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners
Symptoms of nOH may affect approximately one in five people with Parkinson’s Disease
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Otsuka Pharmaceutical Company, Ltd. (Otsuka) and Lundbeck announce that the two companies’ third clinical Phase 3 study of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type will commence in June.
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
Lundbeck today presented data at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. that demonstrates that the Refractory Epilepsy Screening Tool for LGS (REST-LGS) may help healthcare professionals identify patients who may benefit from further clinical evaluation for Lennox-Gastaut syndrome (LGS).
Otsuka Pharma And Lundbeck Announce Initiation Of Two Phase III Trials Of Brexpiprazole In Patients With Bipolar I Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. And Lundbeck To Showcase Safety And Efficacy Data In Treatments For Challenging Mental Health Conditions
Lundbeck Collaborates On Large First-Of-Its Kind Study Of Links Between Genetics And Psychiatric Disorders
Otsuka Pharma And Lundbeck Announce Results Of Brexpiprazole On Symptoms Of Agitation Related To Alzheimer’s-Type Dementia
Health Canada Approves Otsuka Pharma And Lundbeck's REXULTI (Brexpiprazole) As A Treatment For Schizophrenia In Adults